Evidence map›Paper›PMID 30887154›Full record

ArticleJournal of cancer research and clinical oncology2019

Autoantibody against 14-3-3 zeta: a serological marker in detection of gastric cancer.

Jiejie Qin, Shuaibing Wang, Peng Wang, Xiao Wang, Hua Ye, Chunhua Song, Liping Dai, Kaijuan Wang, Binghua Jiang, Jianying Zhang

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of cancer research and clinical oncology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
1.0field-weighted citation impact, top 24% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 15 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 1 institution in 1 country.

Jiejie QinDepartment of Epidemiology and Health statistics, Henan Key Laboratory for Tumor Epidemiology, College of Public Health, Zhengzhou University, 100 Kexue Avenue, Zhengzhou, Henan, China.
Shuaibing WangDepartment of Epidemiology and Health statistics, Henan Key Laboratory for Tumor Epidemiology, College of Public Health, Zhengzhou University, 100 Kexue Avenue, Zhengzhou, Henan, China.
Peng WangDepartment of Epidemiology and Health statistics, Henan Key Laboratory for Tumor Epidemiology, College of Public Health, Zhengzhou University, 100 Kexue Avenue, Zhengzhou, Henan, China.
Xiao WangHenan Academy of Medical and Pharmaceutical Sciences, Zhengzhou University, 40 N Daxue Road, Zhengzhou, Henan, China.
Hua YeDepartment of Epidemiology and Health statistics, Henan Key Laboratory for Tumor Epidemiology, College of Public Health, Zhengzhou University, 100 Kexue Avenue, Zhengzhou, Henan, China.
Chunhua SongDepartment of Epidemiology and Health statistics, Henan Key Laboratory for Tumor Epidemiology, College of Public Health, Zhengzhou University, 100 Kexue Avenue, Zhengzhou, Henan, China.
Liping DaiHenan Academy of Medical and Pharmaceutical Sciences, Zhengzhou University, 40 N Daxue Road, Zhengzhou, Henan, China.
Kaijuan WangDepartment of Epidemiology and Health statistics, Henan Key Laboratory for Tumor Epidemiology, College of Public Health, Zhengzhou University, 100 Kexue Avenue, Zhengzhou, Henan, China.
Binghua JiangHenan Academy of Medical and Pharmaceutical Sciences, Zhengzhou University, 40 N Daxue Road, Zhengzhou, Henan, China.
Jianying ZhangDepartment of Epidemiology and Health statistics, Henan Key Laboratory for Tumor Epidemiology, College of Public Health, Zhengzhou University, 100 Kexue Avenue, Zhengzhou, Henan, China. jianyingzhang@hotmail.com.ORCID http://orcid.org/0000-0003-2938-9526
Zhengzhou University · CN

Funding

General Program of National Natural Science Foundation of China 81372371the Major Project of Science and Technology in Henan Province 16110311400Zhongyuan Scholars Program of Henan Province 162101510006
6 · The paper itself

Abstract

purposeAutoantibody to 14-3-3 zeta was identified in gastric cancer (GC) by serological proteome analysis (SERPA) in our previous study. We comprehensively evaluated its ability to detect GC, determined its association with clinical characteristics, and explored its temporal change in GC patients before and after gastrectomy resection in this study.

methodsAnti-14-3-3 zeta antibody was examined by immunoassay in sera from 465 GC patients and 465 normal individuals, and also in 69 serial sera from 26 GC patients before and after resection.

resultsThe frequency of anti-14-3-3 zeta were significantly higher in GC group than in control group, with AUC of 0.627. The appearance of anti-14-3-3 zeta showed no difference in different tumor stage, tumor size, tumor differentiation, and lymphatic metastasis, but was higher in GC patients with family tumor history than without family tumor history. When anti-14-3-3 zeta was combined with clinical markers (CEA, CA199 and CA724), the sensitivity increased to 52.7%. In the follow-up analysis, the titer of anti-14-3-3 zeta was higher in post-resection sera than pre-resection sera, and no difference was observed in CEA, CA199 and CA724. Anti-14-3-3 zeta showed an increase from negative status to positive status in six patients after resection, while other three clinical markers presented different change in GC patients after resection.

conclusionsAutoantibody against 14-3-3 zeta could be a potential diagnostic biomarker and improve the sensitivity of CEA, CA199 and CA724 in diagnosis of GC. Further largescale studies will be needed to validate its performance in GC patients after resection.

Indexed as

Biomarkers, Tumor14-3-3 ProteinsAutoantibodiesAutoantigensCA-19-9 AntigenCarcinoembryonic AntigenCase-Control StudiesFemaleHumansMaleReproducibility of ResultsROC CurveStomach Neoplasms14-3-3 ProteinsAutoantibodiesAutoantigensBiomarkers, TumorCA-19-9 AntigenCarcinoembryonic AntigenYWHAZ protein, human14-3-3 zetaAutoantibodyBiomarkerGastric cancer

Identifiers

PMID30887154
PMCPMC11810197
OpenAlexW2922227587

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.